Biological
Boostrix clinical trials
- studies test it
- 28
- open now
- 2
- in phase 3
- 15
- first study started
- 2002
Keep track of what changes. Save the Boostrix studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Boostrix
- 24
Studies by the year they started
28 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2006 | 4 |
| 2007 | 4 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2018 | 2 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 15
- Phase 4
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 5
GlaxoSmithKline (20) · University Hospital, Ghent (1) · Mahidol University (1) · Novartis Vaccines (1) · Sanofi (1) · Changchun BCHT Biotechnology Co. (1) · Canadian Immunization Research Network (1) · Oregon Health and Science University (1)
Often tested with
Tested in the same studies.
Meningococcal Vaccines (3) · Adacel (2) · Hepatitis A Vaccines (2) · Fluarix (1) · Shingrix (1) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Pneumococcal Vaccines (1) · 13-valent pneumococcal vaccine (1)
Studies
Open first, then newest update. How each study uses Boostrix is read from its arms, and is right about nine times in ten.
Testing it · 28
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in PregnancyRecruitingPhase 4Canadian Immunization Research NetworkNCT07097012Written as Tdap Vaccine Administration
- A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)Not yet recruitingPhase 1Changchun BCHT Biotechnology Co.NCT07492303Written as Tdap vaccine
- GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of AgeWithdrawnPhase 2/3Minervax ApSNCT06494475Written as Tdap vaccine
- The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)TerminatedPhase 4Oregon Health and Science UniversityNCT05543642Written as Diphtheria, pertussis, and tetanus booster vaccine
- A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of AgeCompletedPhase 3GlaxoSmithKlineNCT05169905Written as dTpa vaccine
- Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune ResponsesCompletedPhase 4University Hospital, GhentNCT02555540Written as Boostrix
- Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian SubjectsCompletedPhase 3GlaxoSmithKlineNCT03311659Written as Boostrix
- Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai WomenCompletedEarly Phase 1Mahidol UniversityNCT03498300Written as Tdap vaccine
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant WomenCompletedPhase 4GlaxoSmithKlineNCT02377349Written as Boostrix™
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058CompletedPhase 4GlaxoSmithKlineNCT00548171Written as Boostrix™
- Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.CompletedPhase 3GlaxoSmithKlineNCT00835237Written as Boostrix®
- Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsCompletedPhase 3GlaxoSmithKlineNCT00385255Written as Boostrix®
- Evaluation of Boostrix™10 Years After Previous Booster VaccinationCompletedPhase 4GlaxoSmithKlineNCT01147900Written as Boostrix™
- US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal DiseaseCompletedPhase 4GlaxoSmithKlineNCT00282295Written as Boostrix®
- Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsCompletedPhase 3GlaxoSmithKlineNCT00346073Written as Boostrix™
- Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese ChildrenCompletedPhase 3GlaxoSmithKlineNCT01988857Written as Boostrix™
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsCompletedPhase 3GlaxoSmithKlineNCT01755689Written as Boostrix®
- Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young AdultsCompletedPhase 3GlaxoSmithKlineNCT01738477Written as Boostrix
- Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and OlderCompletedPhase 3GlaxoSmithKlineNCT02052596Written as Boostrix
- A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' AssaysCompletedPhase 4GlaxoSmithKlineNCT02072525Written as Boostrix®
See all 28 studies that test Boostrix →
Given in every arm · 6 — Boostrix is usual care beside what is tested
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With PlaceboCompletedPhase 2SanofiNCT06015308Written as Tdap vaccine
- Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)CompletedPhase 2LEO PharmaNCT03562377Written as Tdap vaccine
- Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9CompletedPhase 3GlaxoSmithKlineNCT00489970Written as Boostrix
- Viaskin Pertussis Vaccine TrialCompletedPhase 1DBV TechnologiesNCT03035370Written as Boostrix™
- Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in ThailandCompletedPhase 4Universiteit AntwerpenNCT02408926Written as Boostrix
- A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02543918Written as Boostrix®
As the comparator · 12 — what is tested is compared with Boostrix
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgeRecruitingPhase 4BioNTech SENCT07730450Written as Tdap Vaccine
- A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy AdultsRecruitingPhase 1/2GC Biopharma CorpNCT06997627Written as Boostrix®
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsCompletedPhase 1/2GlaxoSmithKlineNCT05073003Written as Boostrix
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid FeverCompletedPhase 1/2GlaxoSmithKlineNCT05480800Written as GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy AdultsCompletedPhase 1GlaxoSmithKlineNCT05613205Written as GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy AdultsStatus unknownPhase 2Green Cross CorporationNCT04238975Written as Boostrix® vaccine
- A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan AdultsCompletedPhase 2GlaxoSmithKlineNCT02676895Written as Boostrix
- Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy WomenCompletedPhase 2GlaxoSmithKlineNCT02360475Written as Boostrix
- Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy WomenCompletedPhase 2GlaxoSmithKlineNCT02753413Written as Boostrix
- Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) VaccineStatus unknownPhase 1/2Green Cross CorporationNCT02813486Written as Biological: Boostrix® vaccine
- Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)CompletedPhase 1NovartisNCT02382913Written as Licensed TdaP booster (Boostrix®)
- Immunogenicity of Adacel® and BOOSTRIX® Vaccines in AdolescentsCompletedPhase 4Sanofi Pasteur, a Sanofi CompanyNCT01629589Written as Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)